Methods to manufacture regulatory T cells for cell therapy
Authors:
Open Access
- 26 March 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 197 (1) , 52-63
Abstract
Regulatory T cell (Treg) therapy has shown promise in early clinical trials for treating graft‐versus‐host disease, transplant rejection and autoimmune disorders. A challenge has been to isolate sufficiently pure Tregs and expand them to a clinical dose. However, there has been considerable progress in the development and optimization of these methods, resulting in a variety of manufacturing protocols being tested in clinical trials. In this review, we summarize methods that have been used to manufacture Tregs for clinical trials, including the choice of cell source and protocols for cell isolation and expansion. We also discuss alternative culture or genome editing methods for modulating Treg specificity, function or stability that could be applied to future clinical manufacturing protocols to increase the efficacy of Treg therapy.Keywords
Funding Information
- Canadian National Transplant Research Program (TFU 127880)
- Networks of Centres of Excellence of Canada (FY17/ES6)
- Canadian Institutes of Health Research (FDN-154304)
- BC Children’s Hospital Research Institute
This publication has 100 references indexed in Scilit:
- The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell HomeostasisScience, 2013
- The battle against immunopathology: infectious tolerance mediated by regulatory T cellsCellular and Molecular Life Sciences, 2011
- Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1Cell, 2011
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T regs ) with Minimal Loss of in Vivo Functional ActivityScience Translational Medicine, 2011
- Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)Journal of Immunotherapy, 2010
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the MorningImmunity, 2009
- Regulatory T Cells Sequentially Migrate from Inflamed Tissues to Draining Lymph Nodes to Suppress the Alloimmune ResponseImmunity, 2009
- Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell TherapyJournal of Immunotherapy, 2009
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsJournal of Experimental Medicine, 2006